Source comparison
How to Use Peptides for Stroke Recovery: Protocol Comparison
Cerebrolysin NGF/BDNF upregulation, neurotrophic support 30–50ml IV daily for 21 days Subacute (7 days–6 months) Phase III RCTs (Cochrane review) Strongest clinical evidence for motor and ADL improvement. Gold standard for research protocols Dihexa HGF mimetic
This comparison does not assign a generated winner or score.
- Cerebrolysin
- NGF/BDNF upregulation, neurotrophic support
- 30–50ml IV daily for 21 days
- Subacute (7 days–6 months)
- Phase III RCTs (Cochrane review)
- Strongest clinical evidence for motor and ADL improvement. Gold standard for research protocols
- Dihexa
- HGF mimetic, c-Met receptor agonist, synaptogenesis
- 5–10mg subcutaneous daily for 8–12 weeks
- Subacute to chronic
- Preclinical only (rodent models)
- Most potent synaptogenic compound per preclinical data. Cognitive deficit focus, no human stroke trials yet
- P21
- CNTF analogue, corticospinal tract regeneration
- 1–2mg subcutaneous daily for 12 weeks
- Subacute
- Preclinical only
- Motor pathway specificity suggests relevance for hemiparesis. Human data pending
- Thymalin
- Thymic peptide, immunomodulation, anti-inflammatory
- 10mg subcutaneous 2–3×/week for 4–8 weeks
- Acute to subacute
- Limited clinical data in stroke
- Indirect mechanism via neuroinflammation reduction. Adjunct potential, not primary intervention